三博脑科 (301293.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

47.2x

Market Cap

CNY 10.41B

MomentumView details →

1D Return

−2.73%

YTD Return

−11.99%

RSI (14)

45.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

47.2x

Market Cap

CNY 10.41B

RSI (14)

45.1

MomentumView details →

1D Return

−2.73%

YTD Return

−11.99%

ProfitabilityView details →

Gross Margin

21.93%

Net Margin

3.43%

EBITDA Margin

13.40%

ROE (TTM)

2.58%

ROA (TTM)

1.56%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

+19.58%

EPS YoY

−45.20%

FCF YoY

+36.62%

Revenue CAGR 3Y

+17.26%

EPS CAGR 3Y

−8.20%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.27x

Current Ratio

1.27x

Quick Ratio

1.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.78B

Net Income (TTM)

60.90M

Op. CF (TTM)

227.21M

Latest newsMore news →

TBP 3Doctors (HK) Limited, a shareholder holding over 5% of Sanbo Brain Hospital, reduced its stake in the company by 1.3968 million shares between June 30 and September 3, 2026, bringing its holding to 13.99% and triggering a 1% threshold disclosure.19h ago

Sanbo Brain Hospital announced its first-half 2026 results: net profit attributable to shareholders fell 53.01% year-on-year to 32.7491 million yuan, while revenue rose 17.42% to 971 million yuan.10d ago

Similar companies

国际医学000516.SZ 迪安诊断300244.SZ 华厦眼科301267.SZ 创新医疗002173.SZ 新里程002219.SZ 盈康生命300143.SZ

Latest newsMore news →

TBP 3Doctors (HK) Limited, a shareholder holding over 5% of Sanbo Brain Hospital, reduced its stake in the company by 1.3968 million shares between June 30 and September 3, 2026, bringing its holding to 13.99% and triggering a 1% threshold disclosure.19h ago Sanbo Brain Hospital announced its first-half 2026 results: net profit attributable to shareholders fell 53.01% year-on-year to 32.7491 million yuan, while revenue rose 17.42% to 971 million yuan.10d ago